For patients with obesity, the current standard of care is a story of appetite suppression, a powerful but sometimes punishing approach. Eolo Pharma, a clinical-stage biotech founded in Montevideo, Uruguay, is writing a different chapter. Its lead candidate, a pill called SANA, aims to treat the disease by making the body burn more energy, not by making the patient eat less. This week, that bet gained significant scientific credibility, with the company announcing the publication of a first-in-human study for SANA in the peer-reviewed journal Nature Metabolism [BioSpace, 2026]. For a small team operating far from traditional biotech hubs, a paper in that tier of journal is more than a milestone. It is a carefully vetted signal that their novel mechanism,activating a process called creatine-dependent thermogenesis,is both safe and showing early signs of efficacy in humans.
The thermogenesis wedge
The scientific premise is distinct from the dominant GLP-1 receptor agonists like semaglutide. Where those drugs work primarily on the brain and gut to reduce hunger and slow digestion, SANA (also known as MVD1) is designed to work directly on fat cells. The compound is a nitroalkene derivative of salicylic acid that targets a specific mitochondrial pathway, prompting white adipose tissue to expend energy as heat [Citeline Scrip, 2024]. In the Phase 1 trial conducted in Australia, the therapy demonstrated it could safely activate this thermogenesis. Early data indicated weight loss and, notably, preservation of lean muscle mass,a side effect profile that, if borne out in larger studies, could differentiate it from treatments that can cause significant muscle wasting [Citeline Scrip, 2024]. The company holds patents for SANA in the US and Europe, securing its intellectual property around this approach [Perplexity Sonar, 2024].
A founding team built on metabolic expertise
Eolo Pharma’s origins are deeply academic. It was founded in 2017 by four PhD scientists whose collective expertise spans the biology of metabolism. The leadership table reflects a deliberate, research-first foundation.
| Role | Founder | Key Background |
|---|---|---|
| CEO | María Pía Garat | Biotechnology engineer |
| Chief Medical Officer | Dr. Carlos Batthyany | Physician and PhD |
| Chief Scientific Officer | Dr. Carlos Escande | Cellular biologist, Principal Investigator at Institut Pasteur Montevideo |
| Co-founder | Dr. Virginia López | Pharmaceutical chemist and PhD |
Dr. Escande’s laboratory at the Institut Pasteur Montevideo specifically focuses on metabolic diseases, aging, and the molecular mechanisms Eolo’s drugs aim to modulate [Google Scholar, 2026]. This academic grounding has helped the company advance its lead asset to human trials on a relatively modest budget. To date, Eolo has raised nearly $7 million in venture capital, anchored by a seed round from regional investor Richi Entrepreneurs in 2024 [Cites-GSS, mid-2024]. The funding has been sufficient to reach this clinical inflection point, but the path ahead is capital-intensive.
The long road from Phase 1
The publication in Nature Metabolism is a powerful validation, but it is only the beginning of a long, expensive, and uncertain regulatory journey. The company’s next steps will be critical and fraught with the challenges common to any early-stage biotech, amplified by its geography.
- Clinical progression. The positive Phase 1 results must be replicated and expanded in larger, longer Phase 2 and 3 trials to prove efficacy and safety to the satisfaction of regulators like the FDA and EMA. These studies will require significantly more capital than the $7 million raised so far.
- The partnership imperative. Eolo’s stated business model is B2B, aiming to license its therapy to a large pharmaceutical company for late-stage development and commercialization [Perplexity Sonar Brief]. To attract a serious partner, it will need to de-risk the asset further, likely through a compelling Phase 2 data readout. While the company reports generating commercial interest, no named partnerships have been disclosed [Cites-GSS, mid-2024].
- The geographic factor. Operating from Uruguay offers cost advantages but may add complexity to navigating US and European regulatory agencies and engaging with global pharma business development teams. Building those bridges will be a key test for the founding team.
For the target patient population,individuals with obesity and related cardiometabolic diseases like type 2 diabetes,the standard of care today is increasingly dominated by injectable GLP-1 drugs. These are highly effective for many, but they come with known side effects, high costs, and supply constraints. They also represent a single mechanistic approach in a disease known for its complexity. Eolo Pharma’s bet is that a pill that safely increases energy expenditure could offer a complementary or alternative option, one that might better preserve muscle and improve metabolic health through a different biological door. The road from a promising paper in Nature Metabolism to a prescription in a doctor’s hand is measured in years and hundreds of millions of dollars. But for this team in Montevideo, the first, crucial step of scientific peer review is now complete.
Sources
- [BioSpace, 2026] Eolo Pharma Publishes First-in-Human Study in Nature Metabolism on Novel Obesity Drug Activating Energy-Burning Pathway | https://www.biospace.com/press-releases/eolo-pharma-publishes-first-in-human-study-in-nature-metabolism-on-novel-obesity-drug-activating-energy-burning-pathway
- [Citeline Scrip, 2024] Eolo Pharma Advances In Obesity With Thermogenesis Approach | https://insights.citeline.com/scrip/business/start-ups-and-smes/emerging-company-profiles/eolo-pharma-advances-in-obesity-with-thermogenesis-approach-GUUOQ2Z235GMXBVA3KF27MTBRA/
- [Perplexity Sonar, 2024] Eolo Pharma company briefing | https://eolo-pharma.com
- [Cites-GSS, mid-2024] In search of an obesity drug: the story of the Latin American company Eolo Pharma | https://cites-gss.com/en/in-search-of-an-obesity-drug-the-story-of-the-latin-american-company-eolo-pharma/
- [Google Scholar, 2026] Carlos Escande academic profile | https://scholar.google.com/citations?user=mn8v4boAAAAJ&hl=en